California Reopening: What You Need to Know | Biocom California

Biocom California invites you to a upcoming webinar where we will review the upcoming changes to Cal/OSHA’s Emergency Temporary Standards (ETS) anticipated to go into effect in June. The discussion will cover modifications to the ETS, how the ETS updates will interact with the newly relaxed CDC guidelines for fully vaccinated individuals, and the bottom-line...

Antiepileptic Drug and Device Trials

The 16th conference on Antiepileptic Drug and Device Trials is held every two years and sponsored by The Epilepsy Study Consortium in collaboration with the University of Pennsylvania and the Epilepsy Foundation. If you have any questions about the conference, please contact Mary Ann Brodie or Tracy DeVito at the Epilepsy Study Consortium. THE IN-PERSON...

QB3 Webinar: John York, Impossible Foods

As Chief Science Officer at Impossible Foods, Dr. John York, PhD, leads a fast-growing R&D team expected to double in size in 2021. Before joining the company in January, York served as the Chair of the Department of Biochemistry and a Professor of Biochemistry at Vanderbilt University from 2012 to 2020, where his laboratory paved...

From The Laboratory To Leadership

From The Laboratory To Leadership turns science-minded managers into capable business leaders. That means they'll get the core management skills they need to fully leverage your company's human capital. In this four-day program, developed exclusively for managers in scientific fields, participants will learn how to … – Create productive teams in a challenging matrix-based team environment...

Biopharma Dealmaking in 2021: Trends and Transformation

In this exclusive webinar, Chris Dokomajilar, founder and CEO of DealForma, and Gilles Toulemonde, CEO of Inova, will present the trends they are tracking and speak to the ongoing digital transformation of biopharma dealmaking. They'll discuss what deals have been done so far in 2021, identify some of the difficulties that pharma companies are experiencing...